Quick Ebola vax development could assist with future outbreaks; GSK touts 'major' Synflorix label expansion;

> The rapid development of Merck's ($MRK) Ebola vaccine--which this week was reported to protect 100% of patients in a Phase III trial--could provide a model for addressing future outbreaks. More

> The Committee for Medicinal Products for Human Use (CHMP) granted GlaxoSmithKline's ($GSK) Synflorix a label expansion to include effectiveness data for protection against invasive pneumococcal disease and pneumonia and acute otitis media caused by the pneumococcus bacterium. Release

> BiondVax ($BVXV) reported that its universal flu vaccine candidate, administered in a Phase II trial 3 years ago, provided patients with increased immunogenicity against influenza strains that didn't exist at the time of the study. Release

And Finally... A 15-year-old developed a vapor-compression refrigeration system requiring minimal power to transport vaccines. More

Read more on